Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses
Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses
复制标题
DOI：
10.2460/ajvr.75.2.141
复制
发表时间：
2014-02-01
影响因子：
1
通讯作者：
Genovese, Ron L.
中科院分区：
文献类型：
--
作者：
Bertone, Alicia L.;Ishihara, Akikazu;Genovese, Ron L.
目的：评价关节内自体蛋白溶液(APS)治疗马骨性关节炎的疗效。动物-40匹自然发病的马。Procedures-APS是由浓缩血浆和白细胞蛋白和浓缩血小板生长因子的双设备系统产生的。马匹随机分为两组，每组20匹，分别关节腔内注射生理盐水(0.9%NaC l)溶液(n=20)或黄芪多糖(APS)(n=20)，在跑步机上进行运动，并根据跛行分级、动态步态分析、关节周长和活动范围进行评估，持续14天。在研究结束时给接受生理盐水的马匹注射APS，并在注射APS前、12周后和52周后对马匹进行跛行和不适评分。结果：与基线或对照组相比，APS组在跛行分级、垂直峰力不对称指数和关节活动范围方面有显著改善。未发现与APS治疗相关的不良反应。客户在12周和52周时评估跛行和舒适度得到改善。对于跛行评分为4，垂直力量不对称，或没有明显的骨赘形成，软骨下硬化，或关节间隙狭窄的马，APS有更大的治疗反应(OR，4.3至30.0)。APS中白介素1受体拮抗剂的浓度是血液中的5.8倍。结论和临床意义-APS关节内给药可被认为是治疗马骨性关节炎的一种有效选择，具有潜在的疾病改善作用。
Objective-To evaluate intra-articular autologous protein solution (APS) for the treatment of osteoarthritis in horses.Animals-40 client-owned horses with naturally occuring osteoarthritis.Procedures-APS was generated from a dual-device system that concentrated plasma and WBC proteins and enriched platelet growth factors. Horses were randomly assigned to receive an intra-articular injection of 5 mL of saline (0.9% NaCl) solution (n = 20) or APS (20), exercised on a treadmill, and evaluated on the basis of lameness grades, kinetic gait analysis, joint circumference, and range of motion for 14 days. Horses that received saline solution were administered APS at termination of the study, and clients scored horses for lameness and discomfort before, 12 weeks after, and 52 weeks after the APS injection.Results-The APS group had significant improvements in lameness grade, asymmetry indices of vertical peak force, and range of joint motion by 14 days, compared with baseline or control group values. No adverse effects associated with APS treatment were evident. Clients assessed lameness and comfort as improved at 12 and 52 weeks. The APS had greater likelihood (OR, 4.3 to 30.0) of a therapeutic response in horses with a lameness score < 4, < 10% vertical force asymmetry, or absence of marked osteophyte formation, subchondral sclerosis, or joint space narrowing. Concentration of interleukin-1 receptor antagonist in APS was 5.8 times that in blood.Conclusions and Clinical Relevance-Intra-articular administration of APS can be considered an effective treatment option for equine osteoarthritis, with the potential for disease-modifying effects.